|
Post by peppy on Jan 6, 2016 14:22:23 GMT -5
A company like TEVA who is trying to get into the Branded specialty market. Perhaps Mylan or Perigo. Somebody will deep pockets can spend 2 to 3 billion and buy a winner. ok kc, I will bite. I know so little about TEVA. Generics (so cost cutters) They do have marketing and distribution? --------------------------------------------------------------------------------------------- I know so little, if TEVA could assure Al Mann that Afrezza could be marketed, at the same price point as fast acting.... If Teva bought technosphere as well.... they have development for....
I agree TEVA.
|
|
|
Post by dictatorsaurus on Jan 6, 2016 14:29:40 GMT -5
Generic companies specialize in generic drugs but they also manufacture and sometimes market branded drugs.
Wouldn't be opposed to TEVA buying out Afrezza.
|
|
|
Post by kc on Jan 6, 2016 14:45:06 GMT -5
|
|
|
Post by mnholdem on Jan 6, 2016 14:53:13 GMT -5
Takeda Pharmaceuticals is the U.S. subsidiary of Takeda Pharmaceutical Company Limited, Japan’s largest drug company. The spinoff was founded in 1998 and ranks among the top 15 drug companies in America, largely because of the Type 2 diabetes drug Actos, which had $3.4 billion in U.S. sales in 2011.
Japanese pharmaceutical company Takeda Pharmaceuticals is the manufacturer of one of the most popular Type 2 diabetes medications, Actos. The drug is linked to an increased risk of bladder cancer. In April 2015, the company settled about 9,000 bladder cancer lawsuits for $2.4 billion.
Japan has one of the most needle-phobic populations on earth. Partnering with Takeda would virtually guarantee early entry into the Japanese market WITHOUT the black box warnings imposed by the FDA. Plus Takeda has a global sales force and has NO DIABETES DRUG that would be threatened by the success of Afrezza. In fact, given the problems they had with not publishing links to cancer associated with Actos, Takeda would likely welcome an insulin that has virtually no side effects.
I don't know if this BP would be the best fit for MannKind Corporation, but I think they should be considered.
NOTE: Takeda's CEO Christophe Weber was offered the CEO job at Sanofi, following Chris Veihmacher's firing, and he turned them down. Olivier Brandicourt was not Sanofi's first choice. Weber, who was Takeda's COO at the time, got the first offer from Sanofi's BoD. That should tell you something about his qualification and that he turned them down speaks to his character.
|
|
|
Post by kc on Jan 6, 2016 15:29:42 GMT -5
They are in the Diabetes space and are a worldwide company.
|
|
|
Post by bill on Jan 6, 2016 15:38:11 GMT -5
The real hangup between MNKD and success is marketing/sales. SNY represents traditional biopharma marketing/sales. High cost; but guaranteed access to the doc and end user. I hope to see MNKD use another marketing channel. A low cost channel such that Afrezza can be priced low. Think of what Amazon did to retailers. Using this new channel, I think MNKD can go it alone and control their destiny. But....they still need financing to get them over the hump. Why shouldn't MNKD go 21st century and market Afrezza through targeted web advertisements ,social media, and online education? Eliminate any traditional sales and do everything in cyberspace.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 15:43:33 GMT -5
The real hangup between MNKD and success is marketing/sales. SNY represents traditional biopharma marketing/sales. High cost; but guaranteed access to the doc and end user. I hope to see MNKD use another marketing channel. A low cost channel such that Afrezza can be priced low. Think of what Amazon did to retailers. Using this new channel, I think MNKD can go it alone and control their destiny. But....they still need financing to get them over the hump. Why shouldn't MNKD go 21st century and market Afrezza through targeted web advertisements ,social media, and online education? Eliminate any traditional sales and do everything in cyberspace. cos its medicine. and not an electronic gadget. It needs support , educate, insurance... I am not saying it cannot be done...Reduce the price and see all payers/patients forming a line
|
|
|
Post by purge on Jan 6, 2016 15:47:25 GMT -5
Isn't this a great way to start off the new year?
|
|
|
Post by vissertrades on Jan 6, 2016 16:04:31 GMT -5
Isn't this a great way to start off the new year? Ah, NO! Today I had to replace both hot water heater AND furnace, now strapped for cash and can't sell MNKD for pennies.
|
|
|
Post by gamblerjag on Jan 6, 2016 16:23:30 GMT -5
Hey topcard, I actually agree that this can happen and also believe in bargain prices but still think 3 billion for MNKD is to low. If we are talking that low of a price there would have to be (guessing) more than one company to buy the whole company or just afrezza... so I'd go to an extreme and say some type of bidding war could occur to get this at 3 billion for Afrezza and 6-8 billion for the company.. or $14-17 pps.. still peanuts for any BP. Hell Hep C brought in 11 billion and 4 billion 3 years ago.. GL.
|
|
topcard
Newbie
Posts: 23
Sentiment: Long
|
Post by topcard on Jan 7, 2016 10:59:59 GMT -5
Bottom line is this - I don't think MNKD can "go it alone", with zero sales force & limited contacts among physicians/insurance companies. I also don't think they can "partner", given their own limited "shelf life" before running out of cash... I just don't think they could financially survive the time needed to implement a new partnership with anyone. I cannot fathom any way they declare bankruptcy, since Al would benefit more from selling as low as $3/share than to allow the company to go bankrupt.
That really only leaves selling the company (or Afrezza).
Interesting that Phizer has decided to never again touch "inhaled insulin" because of the Exubera debacle. Everything done "wrong" with Exubera has been done "right" with Afrezza. But hey - I won't question it...there are plenty of folks out there who still - somehow - equate the two as being nearly identical... no explanation for it, but it is what it is.
I do think it will be a larger player, as they will need anough cash to complete 'superiority' trials, trials for use by children, and offering the product at a price competitive to inuslin pens.
So - MERK? GSK? ELi-Lily? Bayer? J&J?
I suppose TEVA & Takeda could happen too, but I would think one of the "big boys" would make sure that didn't happen. Despite everything that's happened, I'm one of those who firmly believe that big pharma knows & understands precisely how significant Afrezza can be in the treatment of diabetes. I think they know full-well that, if marketed correctly, it could quite easily become the largest selling insulin ever. They don't want a TEVA or Takeda to get that....they'd prefer that nobody ever gets it, but they understand that somebody will.
So - I still think it will be one of the larger, U.S. firms that buys it... and most-likely, the entire company. As for my price estimate? ($5-to-$10) - I stand by that... not happy about it, but MNKD is in no position to demand more than that. I don't think it will be less than that, as there are smaller-pharmas (TEVA & Takeda, for example) waiting in the wings if BP passes this up.
|
|
|
Post by bradleysbest on Jan 7, 2016 11:19:45 GMT -5
Agree unless MNKD can sign a partner for a new TS deal that would provide up front cash until management can figure the termination out. Hopefully a plan B can be executed & the train can keep rolling along (even slowly). I do believe Al will some how provide financing to avoid BK.....IF NEEDED.
|
|